Home 5 Lab Industry Advisor 5 Lab Compliance Advisor 5 Compliance Plans-lca 5 OIG Monthly Work Plan Review: February 2019

OIG Monthly Work Plan Review: February 2019

by | Feb 22, 2019 | Compliance Plans-lca, Essential, Lab Compliance Advisor

This month, there were two new Work Plan items. One of these may have implications for some labs and is detailed below. Characteristics of Part D Beneficiaries at Serious Risk of Opioid Misuse or Overdose Issue: In 2017, there were an estimated 49,000 opioid-related overdose deaths in the United States. In a recent data brief, Opioid Use in Medicare Part D Remains Concerning, OIG found that about 71,000 Part D beneficiaries were at serious risk of misuse or overdose in 2017. Gaining a deeper understanding of the beneficiaries OIG identified as at serious risk of misuse or overdose is an important next step in addressing the crisis. OIG Action: An OIG study will provide needed information about: (1) the characteristics of these beneficiaries, including their demographics and diagnoses; (2) the opioid utilization of these beneficiaries; and (3) the extent to which these beneficiaries have had adverse health effects related to opioids and any overdose incidents.

This month, there were two new Work Plan items. One of these may have implications for some labs and is detailed below.

Characteristics of Part D Beneficiaries at Serious Risk of Opioid Misuse or Overdose

Issue: In 2017, there were an estimated 49,000 opioid-related overdose deaths in the United States. In a recent data brief, Opioid Use in Medicare Part D Remains Concerning, OIG found that about 71,000 Part D beneficiaries were at serious risk of misuse or overdose in 2017. Gaining a deeper understanding of the beneficiaries OIG identified as at serious risk of misuse or overdose is an important next step in addressing the crisis.

OIG Action: An OIG study will provide needed information about: (1) the characteristics of these beneficiaries, including their demographics and diagnoses; (2) the opioid utilization of these beneficiaries; and (3) the extent to which these beneficiaries have had adverse health effects related to opioids and any overdose incidents.

Subscribe to view Essential

Start a Free Trial for immediate access to this article